Baird analyst David Rescott lowered the firm's price target on Merit Medical to $83 from $92 and keeps an Outperform rating on the shares. The firm updated its model following encouraging upside Q1 results nut where theback-end growth ramp likeely weighs on the shares until the second half of the year.
